Uncovering undetected hypoglycemic events

References

• Cryer PE Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes Diabetologia 2002 45 7 937 948 12136392
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 9131 837 853 9742976
   PubMed Web of Science ®Google Scholar
• Zoungas S Patel A Chalmers J Severe hypoglycemia and risks of vascular events and death N Engl J Med 2010 363 15 1410 1418 20925543
   PubMed Web of Science ®Google Scholar
• Cryer PE Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention Alexandria, VA American Diabetes Association 2009
   Google Scholar
• Cryer PE Davis SN Shamoon H Hypoglycemia in diabetes Diabetes Care 2003 26 6 1902 1912 12766131
   PubMed Web of Science ®Google Scholar
• Unger J Parkin C Hypoglycemia in insulin-treated diabetes: a case for increased vigilance Postgrad Med 2011 123 4 81 91 21680992
   PubMed Web of Science ®Google Scholar
• Unger J Parkin C Recognition, prevention, and proactive management of hypoglycemia in patients with type 1 diabetes mellitus Postgrad Med 2011 123 4 71 80 21680991
   PubMed Web of Science ®Google Scholar
• Amiel SA Dixon T Mann R Jameson K Hypoglycaemia in type 2 diabetes Diabet Med 2008 25 3 245 254 18215172
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia Diabetes Care 2005 28 5 1245 1249 15855602
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes – 2012 Diabetes Care 2012 35 Suppl 1 S11 S63 22187469
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Guidance for industry: diabetes mellitus – developing drugs and therapeutic biologics for treatment and prevention Rockville, MD US Food and Drug Administration 2008
   Google Scholar
• Leese GP Wang J Broomhall J Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use Diabetes Care 2003 26 4 1176 1180 12663593
   PubMed Web of Science ®Google Scholar
• Donnelly LA Morris AD Frier BM Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study Diabet Med 2005 22 6 749 755 15910627
   PubMed Web of Science ®Google Scholar
• UK Hypoglycaemia Study Group Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration Diabetologia 2007 50 6 1140 1147 17415551
   PubMed Web of Science ®Google Scholar
• Brod M Christensen T Thomsen TL Bushnell DM The impact of non-severe hypoglycemic events on work productivity and diabetes management Value Health 2011 14 5 665 671 21839404
   PubMed Web of Science ®Google Scholar
• Janssen MM Snoek FJ de Jongh RT Casteleijn S Deville W Heine RJ Biological and behavioural determinants of the frequency of mild, biochemical hypoglycaemia in patients with type 1 diabetes on multiple insulin injection therapy Diabetes Metab Res Rev 2000 16 3 157 163 10867714
   PubMed Web of Science ®Google Scholar
• Fisher M Hypoglycaemia in patients with type 2 diabetes: minimising the risk Br J Diabetes Vasc Dis 2010 10 35 41
   Google Scholar
• McNay EC Cotero VE Mini-review: impact of recurrent hypoglycemia on cognitive and brain function Physiol Behav 2010 100 3 234 238 20096711
   PubMed Web of Science ®Google Scholar
• Warren RE Frier BM Hypoglycaemia and cognitive function Diabetes Obes Metab 2005 7 5 493 503 16050942
   PubMed Web of Science ®Google Scholar
• Whitmer RA Karter AJ Yaffe K Quesenberry CPJr Selby JV Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus JAMA 2009 301 15 1565 1572 19366776
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 24 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• Gerstein HC Miller ME Genuth S ACCORD Study Group Long-term effects of intensive glucose lowering on cardiovascular outcomes N Engl J Med 2011 364 9 818 828 21366473
   PubMed Web of Science ®Google Scholar
• Turnbull FM Abraira C Anderson RJ Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 2009 52 11 2288 2298 19655124
   PubMed Web of Science ®Google Scholar
• Bonds DE Miller ME Bergenstal RM The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study Br Med J 2010 340 b4909 20061358
   PubMed Web of Science ®Google Scholar
• Schopman JE Geddes J Frier BM Frequency of symptomatic and asymptomatic hypoglycaemia in type 1 diabetes: effect of impaired awareness of hypoglycaemia Diabet Med 2011 28 3 352 355 21309845
   PubMed Web of Science ®Google Scholar
• Wild D von Maltzahn R Brohan E Christensen T Clauson P Gonder-Frederick L A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education Patient Educ Couns 2007 68 1 10 15 17582726
   PubMed Web of Science ®Google Scholar
• Gonder-Frederick LA Schmidt KM Vajda KA Psychometric properties of the Hypoglycemia Fear Survey-II for adults with type 1 diabetes Diabetes Care 2011 34 4 801 806 21346182
   PubMed Web of Science ®Google Scholar
• Tupola S Rajantie J Akerblom HK Experience of severe hypoglycaemia may influence both patient’s and physician’s subsequent treatment policy of insulin-dependent diabetes mellitus Eur J Pediatr 1998 157 8 625 627 9727844
   PubMed Web of Science ®Google Scholar
• Zhang Y Wieffer H Modha R Balar B Pollack M Krishnarajah G The burden of hypoglycemia in type 2 diabetes: a systematic review of patient and economic perspectives J Clin Outcomes Manage 2010 17 12 547 557
   Google Scholar
• Frier BM The economic costs of hypoglycaemia Br J Diabetes Vasc Dis 2011 11 Suppl 1 10 12
   Google Scholar
• Harris SB Leiter LA Yale J-F Chaisson J-L Kleinstiver P Sauriol L Out of pocket costs of managing hyperglycemia and hypoglycemia in patients with type 1 diabetes and insulin-treated type 2 diabetes Can J Diabetes 2007 31 1 25 33
   Google Scholar
• Curkendall SM Zhang B Lenhart GM Impact of hypoglycemia events on short-term disability and absenteeism in patients with type 2 diabetes [Abstract] Diabetes 2011 60 Suppl 1 A549 A573
   Google Scholar
• Unger J Insulin initiation and intensification in patients with type 2 diabetes mellitus for the primary care physician Diabetes Metab Syndr Obes 2011 4 253 261 21792324
   PubMedGoogle Scholar
• California Healthcare Foundation/American Geriatrics Society Guidelines for improving the care of the older person with diabetes mellitus J Am Geriatr Soc 2003 51 Suppl 5 S265 S280 12694461
   PubMed Web of Science ®Google Scholar
• Munshi MN Segal AR Suhl E Frequent hypoglycemia among elderly patients with poor glycemic control Arch Intern Med 2011 171 4 362 364 21357814
   PubMedGoogle Scholar
• Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 1993 329 14 977 986 8366922
   PubMed Web of Science ®Google Scholar
• Hoelzel W Miedema K Development of a reference system for the international standardization of HbA1c/glycohemoglobin determinations J Int Fed Clin Chem 1996 9 2 62 67 10163516
   PubMedGoogle Scholar
• Hermansen K Davies M Derezinski T Ravn GM Clauson P Home P A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes Diabetes Care 2006 29 6 1269 1274 16732007
   PubMed Web of Science ®Google Scholar
• Polonsky WH Fisher L Schikman CH A structured self-monitoring of blood glucose approach in type 2 diabetes encourages more frequent, intensive, and effective physician interventions: results from the STeP study Diabetes Technol Ther 2011 13 8 797 802 21568751
   PubMed Web of Science ®Google Scholar
• Rodbard HW Schnell O Unger J Use of an automated decision support tool optimizes clinicians ability to interpret and appropriately respond to structured self-monitoring of blood glucose data Diabetes Care 2012 2 16 [Epub ahead of print]
   Web of Science ®Google Scholar
• Jones TW Porter P Sherwin RS Decreased epinephrine responses to hypoglycemia during sleep N Engl J Med 1998 338 23 1657 1662 9614256
   PubMed Web of Science ®Google Scholar
• Kubiak T Hermanns N Schreckling HJ Kulzer B Haak T Evaluation of a self-management-based patient education program for the treatment and prevention of hypoglycemia-related problems in type 1 diabetes Patient Educ Couns 2006 60 2 228 234 16442464
   PubMed Web of Science ®Google Scholar
• Strange P Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes J Diabetes Sci Technol 2007 1 4 540 548 19885117
   PubMedGoogle Scholar
• Brunton S Safety and effectiveness of modern insulin therapy: the value of insulin analogs Consultant 2009 Suppl S13 19
   Google Scholar
• Clore JN Thurby-Hay L Basal insulin therapy Curr Diab Rep 2004 4 5 342 345 15461898
   PubMedGoogle Scholar
• Arnolds S Kuglin B Kapitza C Heise T How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes Int J Clin Pract 2010 64 10 1415 1434 20618882
   PubMed Web of Science ®Google Scholar
• Heise T Nosek L Ronn BB Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes Diabetes 2004 53 6 1614 1620 15161770
   PubMed Web of Science ®Google Scholar
• Valentine WJ Jendle J Saraheimo M Thorsteinsson B Pollock RF Lammert M Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands Diabet Med 9 27 2011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Birkeland KI Home PD Wendisch U Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine Diabetes Care 2011 34 3 661 665 21270174
   PubMed Web of Science ®Google Scholar
• Heise T Hovelmann U Nosek L Bottcher SG Granhall C Haahr H Insulin degludec: two-fold longer half-life and more consistent pharmacokinetic profile than insulin glargine Diabetologia 2011 54 Suppl 1 S425
   Google Scholar
• Kurtzhals P Heise T Strauss HM Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec [Abstract] Diabetes 2011 60 Suppl 1A LB12
   Google Scholar
• Heller S Francisco AM Pei H Russell-Jones D Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in type 1 diabetes [Abstract] Diabetes 2011 60 Suppl 1 A19
   Google Scholar
• Garber AJ King AB Francisco A Endahl LA Hollander PA Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in people with type 2 diabetes [Abstract] Diabetes 2011 60 Suppl 1 A20
   Google Scholar
• Meneghini L Atkin S Bain S Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes [Abstract] Diabetes 2011 60 Suppl 1A LB10 11
   Google Scholar
• Siebenhofer A Plank J Berghold A Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus Cochrane Database Syst Rev 2006 2 CD003287 16625575
   PubMedGoogle Scholar
• Home PD Lindholm A Riis A Insulin aspart versus. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial Diabet Med 2000 17 11 762 770 11131100
   PubMed Web of Science ®Google Scholar
• Heller SR Amiel SA Mansell P Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. UK Lispro Study Group Diabetes Care 1999 22 10 1607 1611 10526722
   PubMed Web of Science ®Google Scholar
• Yamada S Insulin glulisine in the management of diabetes Diabetes Metab Syndr Obes 2009 2 111 115 21437124
   PubMedGoogle Scholar
• Heinemann L Weyer C Rauhaus M Heinrichs S Heise T Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart Diabetes Care 1998 21 11 1910 1914 9802742
   PubMed Web of Science ®Google Scholar
• Boehm BO Home PD Behrend C Kamp NM Lindholm A Premixed insulin aspart 30 versus. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients Diabet Med 2002 19 5 393 399 12027927
   PubMed Web of Science ®Google Scholar
• Boehm BO Vaz JA Brondsted L Home PD Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes Eur J Intern Med 2004 15 8 496 502 15668084
   PubMedGoogle Scholar
• McNally PG Dean JD Morris AD Wilkinson PD Compion G Heller SR Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes Diabetes Care 2007 30 5 1044 1048 17277042
   PubMed Web of Science ®Google Scholar
• Heise T Tack CJ Cuddihy R A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial Diabetes Care 2011 34 3 669 674 21285389
   PubMed Web of Science ®Google Scholar
• Davis SN Horton ES Battelino T Rubin RR Schulman KA Tamborlane WV STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects Diabetes Technol Ther 2010 12 4 249 255 20210562
   PubMed Web of Science ®Google Scholar
• Bergenstal RM Tamborlane WV Ahmann A Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase Diabetes Care 2011 34 11 2403 2405 21933908
   PubMed Web of Science ®Google Scholar
• Choudhary P Shin J Wang Y Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk Diabetes Care 2011 34 9 2023 2025 21868778
   PubMed Web of Science ®Google Scholar
• Pearson TL Practical aspects of insulin pen devices J Diabetes Sci Technol 2010 4 3 522 531 20513316
   PubMedGoogle Scholar
• Lee WC Balu S Cobden D Joshi AV Pashos CL Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data Clin Ther 2006 28 10 1712 1725 17157128
   PubMed Web of Science ®Google Scholar
• Spiller HA Borys DJ Ryan ML Sawyer TS Wilson BL Unintentional therapeutic errors involving insulin in the ambulatory setting reported to poison centers Ann Pharmacother 2011 45 1 17 22 21119100
   PubMed Web of Science ®Google Scholar
• Pfutzner A FlexPen for the delivery of insulin: accuracy, injection force and patient preference Expert Rev Med Devices 2009 6 2 115 123 19298158
   PubMed Web of Science ®Google Scholar
• Campbell RK Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus Clin Ther 2011 33 5 511 527 21665040
   PubMed Web of Science ®Google Scholar
• Buse JB Bergenstal RM Glass LC Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial Ann Intern Med 2011 154 2 103 112 21138825
   PubMed Web of Science ®Google Scholar
• Yoon NM Cavaghan MK Brunelle RL Roach P Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting Clin Ther 2009 31 7 1511 1523 19695400
   PubMed Web of Science ®Google Scholar
• Unger J Nadeau DA Def ining the role of incretin mimetic therapy in the management of type 2 diabetes J Fam Pract 2007 56 Suppl 12 S4 S10 18664341
   PubMedGoogle Scholar
• Cobden D Lee WC Balu S Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus Pharmacotherapy 2007 27 7 948 962 17594200
   PubMed Web of Science ®Google Scholar
• Misurski D Lage MJ Fabunmi R A comparison of costs among patients with type 2 diabetes who initiated therapy with exenatide or insulin glargine Appl Health Econ Health Policy 2009 7 4 245 254 19905038
   PubMedGoogle Scholar